METHODS AND PRODUCTS FOR TREATING INFLAMMATION
Pharmaceutical compositions comprising an isolated form of a compound of Formula I or IA (e.g., anatabine or S-(−)-anatabine) or a salt thereof can be used to treat disorders comprising an inflammatory component, including chronic, low-level inflammation. Compounds of Formula I also can be provided, for example, in other vehicles such as beverage products and consumer products such as lotions and creams.
1 . A method of reducing a symptom in an individual of a disorder comprising an NFκB-mediated inflammatory component, comprising administering to the individual a composition comprising a therapeutically effective dose of an isolated form of a compound of Formula I
wherein:
R represents hydrogen or C 1 -C 5 alkyl;
R′ represents hydrogen or C 1 -C 7 alkyl; and
X represents halogen or C 1 -C 7 alkyl,
or a salt thereof.
2 . The method of claim 1 wherein the compound is anatabine or S-(−)-anatabine.
3 . The method of claim 1 wherein the composition comprises a salt of anatabine or S-(−)-anatabine.
4 . The method of claim 1 wherein the NFκB-mediated inflammatory component is chronic inflammation.
5 . The method of claim 1 wherein the disorder is selected from the group consisting of an autoimmune disorder, a vascular inflammatory disorder, a gastrointestinal inflammatory disorder, a neurodegenerative disorder, cancer, an upper respiratory tract infection, a joint disorder, seizure disorder, and an autism spectrum disorder.
6 . The method of claim 5 wherein the disorder is an autoimmune disorder and the autoimmune disorder is selected from the group consisting of thyroiditis, rheumatoid arthritis, and diabetes.
7 . The method of claim 5 wherein the disorder is a vascular inflammatory disorder and the vascular inflammatory disorder is selected from the group consisting of atherosclerosis, coronary artery disease, cerebrovascular disease, peripheral vascular disease, and inflammation-induced myocarditis.
8 . The method of claim 5 wherein the disorder is a neurodegenerative disorder and the neurodegenerative disorder is selected from the group consisting of Alzheimer's disease and Parkinson's disease, and wherein the compound of Formula I is S-(−)-anatabine.
9 . The method of claim 5 wherein the disorder is a cancer.
10 . The method of claim 5 wherein the disorder is an upper respiratory tract infection and the upper respiratory tract infection is a cold.
11 . The method of claim 5 wherein the disorder is a joint disorder and the joint disorder is selected from the group consisting of osteoarthritis and degenerative joint disease.
12 . The method of claim 5 wherein the disorder is a seizure disorder or an autism spectrum disorder.
13 . The method of claim 1 wherein the dose is in an extended release formulation.
14 . The method of claim 1 wherein the dose is from about 0.1 to about 1.5 mg/kg body weight.
15 . The method of claim 1 further comprising administration of a second therapeutic agent.
16 . A method of reducing a risk in an individual of developing a disorder comprising an NFκB-mediated inflammatory component, comprising administering to the individual a composition comprising a therapeutically effective dose of an isolated form of a compound of Formula I or a salt thereof.
17 . A beverage product suitable for human consumption comprising a beverage container containing a liquid medium and an isolated form of a compound of Formula I
wherein:
R represents hydrogen or C 1 -C 5 alkyl;
R′ represents hydrogen or C 1 -C 7 alkyl; and
X represents halogen or C 1 -C 7 alkyl,
or a salt thereof.
18 . The beverage product of claim 17 wherein the compound is anatabine or S-(−)-anatabine.
19 . A consumer product selected from the group consisting of paste, cream, lotion, moisturizer, sunscreen, toothpaste, mouthwash, and an inhaler, wherein the product contains an isolated form of a compound of Formula I:
wherein:
R represents hydrogen or C 1 -C 5 alkyl;
R′ represents hydrogen or C 1 -C 7 alkyl; and
X represents halogen or C 1 -C 7 alkyl,
or a salt thereof.
20 . The consumer product of claim 19 wherein the compound is anatabine or S-(−)-anatabine.